ad
This Article
Right arrow Images Only
Right arrow Full Version
Services
Right arrow E-mail this link to a friend
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Section 1
Section 2
Section 3
Section 4
Section 5
Appendices
Right arrow Earn CME - What's This?
Related Collections
Right arrowRelated Articles

The first 300 words of the full text of this section appear below.

Section 3. Summaries of Infectious Diseases

Varicella-Zoster Infections

Clinical Manifestations
Etiology
Epidemiology
Diagnostic Tests
Treatment
Isolation of the Hospitalized Patient
Control Measures
Care of Exposed People

CLINICAL MANIFESTATIONS

Primary infection results in varicella (chickenpox), manifesting as a generalized, pruritic, vesicular rash typically consisting of 250 to 500 lesions in varying stages of development and resolution (crusting), mild fever, and other systemic symptoms. Complications include bacterial superinfection of skin lesions, pneumonia, central nervous system involvement (acute cerebellar ataxia, encephalitis), thrombocytopenia, and other rare complications, such as glomerulonephritis, arthritis, and hepatitis. Varicella tends to be more severe in adolescents and adults than in young children. Breakthrough chickenpox cases usually are mild and can occur in immunized children, as described later in Active Immunization (p 721). Reye syndrome can follow cases of chickenpox, although today Reye syndrome is very rare because of decreased use of salicylates during varicella. In immunocompromised children, progressive, severe varicella characterized by continuing eruption of lesions and high fever persisting into the second week of illness as well as encephalitis, hepatitis, and pneumonia can develop. Hemorrhagic varicella is much more common among immunocompromised patients than among immunocompetent hosts. Pneumonia is relatively less common among immunocompetent children but is the most common complication in adults. In children with human immunodeficiency virus (HIV) infection, recurrent varicella or disseminated herpes zoster can develop. Severe and even fatal varicella has been reported in otherwise healthy children receiving intermittent courses of high-dose corticosteroids (greater than 2 mg/kg of prednisone or equivalent) for treatment of asthma and other illnesses. The risk especially is high when corticosteroids are given during the incubation period for chickenpox.

Varicella-zoster virus (VZV) establishes latency in the dorsal root ganglia during primary infection. Reactivation results in herpes zoster ("shingles"), characterized by grouped vesicular lesions in the distribution of 1 to 3 . . . [Go to Full Text]


Related Articles

Summary of Major Changes in the 2009 Red Book
Red Book 2009 2009: XXIX. [Extract] [Full Text]

Vaccine Safety and Contraindications
Red Book 2009 2009: 40-41. [Extract] [Full Text]

Reporting of Adverse Events
Red Book 2009 2009: 42-51. [Extract] [Full Text]

Scheduling Immunizations
Red Book 2009 2009: 21-31. [Extract] [Full Text]

Immune Globulin Intravenous
Red Book 2009 2009: 58-61. [Extract] [Full Text]

Pregnancy
Red Book 2009 2009: 70-72. [Extract] [Full Text]

Immunocompromised Children
Red Book 2009 2009: 72-86. [Extract] [Full Text]

Children With Chronic Diseases
Red Book 2009 2009: 86a-87a. [Extract] [Full Text]

Active Immunization After Exposure to Disease
Red Book 2009 2009: 87-88. [Extract] [Full Text]

Children in Residential Institutions
Red Book 2009 2009: 90-92. [Extract] [Full Text]

Transmission of Infectious Agents via Human Milk
Red Book 2009 2009: 119a-124a. [Extract] [Full Text]

Recommendations for Inclusion or Exclusion
Red Book 2009 2009: 127-131. [Extract] [Full Text]

Infectious Diseases—Epidemiology and Control
Red Book 2009 2009: 131-138. [Extract] [Full Text]

Rubella
Red Book 2009 2009: 579-584. [Extract] [Full Text]

Human Immunodeficiency Virus Infection
Red Book 2009 2009: 380a-400a. [Extract] [Full Text]

Measles
Red Book 2009 2009: 444-455. [Extract] [Full Text]

Mumps
Red Book 2009 2009: 468-472. [Extract] [Full Text]

Antiviral Drugs
Red Book 2009 2009: 777-782. [Extract] [Full Text]